Shanghai Henlius Biotech

OverviewSuggest Edit

Shanghai Henlius Biotech provides clinical-stage biopharmaceutical services. The company focuses on the development, production, and commercialization of mAb (monoclonal antibody) biosimilar drugs, bio-betters, and mAbs. Its products in development cover a variety of therapeutic areas including oncology and autoimmune diseases.

TypePrivate
Founded2009
Websitehenlius.com

Latest Updates

Employees (est.) (Jul 2019)127(+4%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Shanghai Henlius Biotech Financials and Metrics

Summary Metrics

Founding Date

2009

Shanghai Henlius Biotech total Funding

$346 m

Shanghai Henlius Biotech latest funding size

$156 m

Time since last funding

3 years ago

Shanghai Henlius Biotech investors

Shanghai Henlius Biotech's latest funding round in July 2018 was reported to be $156 m. In total, Shanghai Henlius Biotech has raised $346 m
Show all financial metrics

Shanghai Henlius Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

D

60/100

SecurityScorecard logo

Shanghai Henlius Biotech Online and Social Media Presence

Embed Graph

Shanghai Henlius Biotech Frequently Asked Questions

  • When was Shanghai Henlius Biotech founded?

    Shanghai Henlius Biotech was founded in 2009.

  • How many employees does Shanghai Henlius Biotech have?

    Shanghai Henlius Biotech has 127 employees.

  • Who are Shanghai Henlius Biotech competitors?

    Competitors of Shanghai Henlius Biotech include Corcept Therapeutics, tella and Immunovative Therapies.